Growth Continues in Infectious Disease Diagnostics
|
By LabMedica International staff writers Posted on 24 Nov 2015 |
Global testing for infectious diseases has reached USD 16.8 Billion and the segment continues to expand from demand, growing infrastructure in emerging nations, and intense competition, according to a new healthcare market study.
The findings were presented in the latest Kalorama Information (New York, NY, USA) report “The World Market for Infectious Disease Testing.” Infectious diseases are also the frequent target of novel diagnostic technology applications including PCR-alternative molecular amplification methods, next-generation sequencing (NGS), microarrays, and mass spectrometry. Advancements in automation and microfluidics have allowed for proliferation of infectious disease testing across settings and institutions—from traditional sites such as reference labs through physician office laboratories (POLs) and mobile clinics in the developing world.
“Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry” said Emil Salazar, IVD industry analyst and author of the report, “Occasional explosive market growth in the infectious disease test market can occur with the emergence of new disease threats or acceptance of new routine screening procedures.”
Conventional real-time PCR offers improved specificity and sensitivity regardless of test setting and is playing a strong role in advanced therapeutics such as antiretroviral therapy. Infectious disease diagnostics also take on added importance beyond individual clinical cases in the surveillance and control of healthcare-threatening pathogens such as antimicrobial-resistant microorganisms.
"No one technology can satisfy clinical demand for infectious disease diagnostics," said Salazar. Molecular tests can provide crucial genus- and species-specific information for investigating epidemics and studying antimicrobial resistance and other relevant traits. For the foreseeable future, laboratories will continue to rely upon traditional identification and antimicrobial sensitivity tests (ID/AST) and immunoassays for routine testing and on molecular tests for hard-to-culture pathogens and the most time-critical infections.
The disparity in infectious disease test market growth rates is evident between countries with established healthcare systems and countries of the developing world. The developed world is projected to be held to an under-4% average annual growth rate in terms of infectious disease test sales through 2020. Countries such as China, India, and in Latin America, on the other hand, remain in the process of implementing rapid testing as part of infectious disease screening and molecular diagnostics. “Even established infectious disease testing tools such as culture ID/AST can expect more robust rates of growth in the developing world as labs update their microbiology testing to automated platforms and increase capacity to handle increased patient volume,” said Salazar.
Related Links:
Kalorama Information
The World Market for Infectious Disease Tests, report
The findings were presented in the latest Kalorama Information (New York, NY, USA) report “The World Market for Infectious Disease Testing.” Infectious diseases are also the frequent target of novel diagnostic technology applications including PCR-alternative molecular amplification methods, next-generation sequencing (NGS), microarrays, and mass spectrometry. Advancements in automation and microfluidics have allowed for proliferation of infectious disease testing across settings and institutions—from traditional sites such as reference labs through physician office laboratories (POLs) and mobile clinics in the developing world.
“Infectious disease tests are one of the most dynamic spaces in the in vitro diagnostics (IVD) industry” said Emil Salazar, IVD industry analyst and author of the report, “Occasional explosive market growth in the infectious disease test market can occur with the emergence of new disease threats or acceptance of new routine screening procedures.”
Conventional real-time PCR offers improved specificity and sensitivity regardless of test setting and is playing a strong role in advanced therapeutics such as antiretroviral therapy. Infectious disease diagnostics also take on added importance beyond individual clinical cases in the surveillance and control of healthcare-threatening pathogens such as antimicrobial-resistant microorganisms.
"No one technology can satisfy clinical demand for infectious disease diagnostics," said Salazar. Molecular tests can provide crucial genus- and species-specific information for investigating epidemics and studying antimicrobial resistance and other relevant traits. For the foreseeable future, laboratories will continue to rely upon traditional identification and antimicrobial sensitivity tests (ID/AST) and immunoassays for routine testing and on molecular tests for hard-to-culture pathogens and the most time-critical infections.
The disparity in infectious disease test market growth rates is evident between countries with established healthcare systems and countries of the developing world. The developed world is projected to be held to an under-4% average annual growth rate in terms of infectious disease test sales through 2020. Countries such as China, India, and in Latin America, on the other hand, remain in the process of implementing rapid testing as part of infectious disease screening and molecular diagnostics. “Even established infectious disease testing tools such as culture ID/AST can expect more robust rates of growth in the developing world as labs update their microbiology testing to automated platforms and increase capacity to handle increased patient volume,” said Salazar.
Related Links:
Kalorama Information
The World Market for Infectious Disease Tests, report
Latest Industry News
- Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
- Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
- Siemens Healthineers Begins Transition Toward Standalone Olyrian Diagnostics Business
- Agilent Completes Acquisition of Digital Pathology Platform Developer Proscia
- New Diagnostics Company Onvaro Formed to Expand Decentralized Testing
- Illumina Selected to Support National Genomics Study for Personalized Healthcare in Singapore
- Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk
- CE-Marked IVD Sequencing Platform Launches Across Ten EU Countries
- Real Diagnostics Adds Saliva-Based Periodontal Testing With SimplyTest Deal
- Collaboration Brings Tumor-Informed MRD Monitoring to Breast Cancer Care in Abu Dhabi
- Qiagen Agrees to Go Private Through EQT-Led Acquisition
- Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
- Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
- Myriad Genetics to Sell Prenatal Testing Portfolio to Labcorp
- Alzheimer’s Progression Blood Test Gains U.S. Patent Ahead of Planned Launch
- Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition
Channels
Clinical Chemistry
view channel
AI Predicts Kidney Stone Composition From Routine Urine Tests
Kidney stones are a common and painful condition, affecting approximately one in 11 Americans, with lifetime recurrence rates of 60% to 80%. Identifying stone composition is important for guiding treatment... Read more
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read moreMolecular Diagnostics
view channelAMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health
Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women.... Read more
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more
AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more
Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more







